The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so far

Research output: Contribution to journalArticle

Institutes & Expert groups

  • UCLA - Univerity of California Los Angeles - David Geffen School of Medicine
  • University Hospital Essen, Essen

Documents & links

Abstract

At present, prostate cancer remains the second most occurring cancer in men, in Europe. Treatment efficacy for therapy of advanced metastatic disease, and metastatic castration-resistant prostate cancer in particular is limited. Prostate-specific membrane antigen (PSMA) is a promising therapeutic target in prostate cancer, seeing the high amount of overexpression on prostate cancer cells. Clinical investigation of PSMA-targeted radionuclide therapy has shown good clinical efficacy. However, adverse effects are observed of which salivary gland hypofunction and xerostomia are among the most prominent. Salivary gland toxicity is currently the dose-limiting side effect for PSMA-targeted radionuclide therapy, and more specifically for PSMA-targeted alpha therapy. To date, mechanisms underlying the salivary gland uptake of PSMA-targeting compounds and the subsequent damage to the salivary glands remain largely unknown. Furthermore, preventive strategies for salivary gland uptake or strategies for treatment of salivary gland toxicity are needed. This review focuses on the current knowledge on uptake mechanisms of PSMA-targeting compounds in the salivary glands and the research performed to investigate different strategies to prevent or treat salivary gland toxicity.

Details

Original languageEnglish
Pages (from-to)30-39
Number of pages10
JournalNuclear Medicine and Biology
Volume98-99
DOIs
Publication statusPublished - 2021

Keywords

  • Prostate cancer, PSMA-targeted radionuclide therapy, Salivary gland toxicity, Xerostomia

ID: 7126162